Drugs / 18F-PSMA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04461509 | Apr 2021 → Sep 2024 | male reproductive system neoplasm, prostate neoplasm | Alessandro D'Agnolo | Completed | No outcome recorded |
| Phase 2 | NCT04775602 | Jul 2020 → Apr 2023 | prostate cancer | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Completed | No outcome recorded |
Press releases naming this drug 10 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04461509 ↗ |
| Modality | Diagnostic / imaging agent | “additional diagnostic role of 18F-PSMA PET/CT” NCT04775602 ↗ |
| Route | Intravenous | “18F-PSMA will be injected intravenously” NCT04775602 ↗ |